The shadow of generic competition has long loomed above copyright’s famous drug, PDE5 Inhibitor, raising questions about the prospects of related medicinal holdings. While initial times saw substantial profits, the exclusivity end has opened the way for less expensive alternatives, likely diminishing revenue and presenting a real risk for shareho